Company Focus
AbbVie
Latest AbbVie News
Biotechnology
The European Commission has approved Danish biotech Genmab and US pharma major AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, widening the bispecific antibody’s European label into an earlier treatment setting 7 July 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing atacicept and other targeted therapies for serious immunological and kidney diseases with high unmet medical need.
Latest News & Features of interest to AbbVie
Biosimilars
Israel based Teva Pharmaceutical Industries and South Korea’s Samsung Bioepis have entered into a license and commercialization agreement for Opuviz (aflibercept), a biosimilar referencing Eylea (aflibercept), in Canada. 10 July 2026
Biosimilars
Israeli drugmaker Teva Pharmaceutical Industries has expanded its biosimilars pipeline through a global licensing agreement with Polpharma Biologics for a proposed copy of Roche’s multiple sclerosis drug Ocrevus (ocrelizumab). 9 July 2026
Biotechnology
The China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for Padcev (enfortumab vedotin) in combination with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) as neoadjuvant treatment (before surgery), and then continued after cystectomy (surgery) as adjuvant treatment (after surgery), for adults with muscle-invasive bladder cancer (MIBC), regardless of their eligibility for cisplatin-containing chemotherapy. 9 July 2026
Biotechnology
Heidelberg, Germany-based research institute BioMed X and German drug major Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s US R&D headquarters in Ridgefield, Connecticut. 9 July 2026
Biotechnology
UK biotech company Alchemab Therapeutics has secured a £25 million ($34 million) Series A extension from the British Business Bank, in what the Bank says is its largest direct investment in a life sciences company. 9 July 2026
Biotechnology
US precision oncology biotech Stipple Bio has appointed Roland Gendron as chief business officer as it prepares to move lead candidate STP-100 into early clinical studies. 8 July 2026
Biotechnology
French genetic medicines company Cyllene Therapeutics has raised 33 million euros ($38 million) in series C financing to support development of its lead neuro-urology candidate EG110A, as the company rebrands from EG 427 and moves closer to late-stage clinical testing. 8 July 2026
Pharmaceutical
Florida, USA-based clinical-stage biopharma DemeRx has appointed Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from pre-clinical research through clinical development. 8 July 2026
Biotechnology
Privately-held German drugmaker Boehringer Ingelheim has signed a licensing agreement with German biotech Prime Vector Technologies (PVT), gaining access to its Orf virus (ORFV) platform for the development of next-generation cancer vaccines. 7 July 2026
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. 7 July 2026
Latest In Brief for AbbVie
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze